Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

Date
December 21, 2016

UTRECHT, The Netherlands, Dec. 21, 2016 (GLOBE NEWSWIRE)

Today, Merus N.V. (NASDAQ:MRUS) and Incyte Corporation (NASDAQ:INCY) announced that they have entered a global strategic research collaboration focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs.

Merus will host a conference call today to discuss this strategic research collaboration at 8:30 a.m. ET, 2:30 p.m. CET. Participants may access the call by dialing 866-978-9968 in the U.S. or 646-722-4972 outside the U.S. and referencing conference ID number 72944512#. The conference call will also be available by webcast on the Investor Relations page of Merus’ website, www.merus.nl. An audio replay of the call will be available from 11:30 a.m. ET on December 21, 2016 until 11:30 a.m. ET on January 4, 2017. To access the replay from both within and outside the U.S., dial 866-535-8030. The participant passcode is 680343#.

Contacts:

Eliza Schleifstein, Media
+1 973 361 1546
eliza@argotpartners.com

Kimberly Minarovich, Investors
+1 646 368 8014
kimberly@argotpartners.com